1.	Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR200066_003, NCT01016483
2.	Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR 200066-007, 2012-002669-37, NCT01693068
3.	Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR 200066-006, NCT01390818
4.	A Multicentre, Open Label, Phase I Trial in Japan of the MEK Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR 200066-010, NCT01668017
5.	Oral Bioavailability and Mass Balance Trial With Pimasertib Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 65 Sponsor: Pharmaceutical / Industry Protocol IDs: EMR 200066-008, 2012-002562-12, NCT01713036